Glycosylation and stability of mature HIV envelope glycoprotein conformation under various conditions  by Papandreou, M.J. et al.
FEBS 16576 FEBS Letters 379 (1996) 171-176 
Glycosylation and stability of mature HIV envelope glycoprotein 
conformation under various conditions 
M.J. Papandreoua,*, T. Idziorekb, R. Miquelis”, E. Fenouillet” 
“IFR Jean Roche. URA 1455, FacultP de MPdecine Nord, Bd. II Dramard 13916, Marseille Cedex 20. France 
bU 415, Institut Pasteur, Lille, France 
Received 13 November 1995 
Abstract The role of the glycans of the mature human immu- 
nodeficiency virus (HIV) envelope (gp160) in its stability in vari- 
ous conditions was studied. gp160 conformation was monitored 
through its subsequent ability to bind [?]CD4. Treatment of 
glycosylated (CHO+) gp160 with (i) sodium dodecyl sulfate 
(SDS) concentrations above 0.01% impaired subsequent CD4 
binding while 0.3% SDS abolished it; (ii) P-mercaptoethanol 
(MSH) concentrations above 0.01% impaired CD4 binding while 
0.03% MSH abolished it; (iii) 2 M guanidine-HCl had no effect; 
(iv) temperatures between 50°C and 80°C altered CD4 binding 
while, above 8O”C, the binding was abolished; (v) CD4 binding 
was decreased by 50% by 2 freeze-thaw cycles but was not further 
affected by subsequent (up to 15) cycles; (vi) gp160 incubation in 
serum or cell lysate had no effect on CD4 binding. Glycanase 
treated (CHO-) gp160 binding activity was only 3-fold lower 
than that of CHO+ gp160. Only 2 M guanidine-HCI and heating 
at 70°C differentially affected the binding of CHO+ and CHO- 
gp160, the effects being larger for CHO- gp160. CHO- gp160 
binding was impaired after incubation in either serum or cell 
lysate. Thus, glycans stabilize gp160 conformation in some envi- 
ronments. However, CHO- gp160 appears to be resistant to 
denaturation as compared to other glycoproteins reported in the 
literature. 
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1. Introduction 
N-linked glycans of glycoproteins are important for intracel- 
lular routing, biosynthesis, folding, biological activity, antigen- 
icity and protection against proteolytic and physico-chemical 
degradations [l-S]. Thus, glycosylation is a post-translational 
modification which affects many characteristics of a glycopro- 
tein. 
For many viral envelope (Env) glycoproteins, glycans con- 
tribute to various steps of the virus cycle, e.g. folding, virus 
budding, infectivity and antigenicity changes [1,6,7]. Early in 
the 90’s, the involvement of glycans of the human immunodefi- 
ciency virus type-l (HIV-l) Env in such phenomena was stud- 
ied [3,6]: glycans are necessary both to create the functional 
conformation of Env [3,6] and for its efficient intracellular 
transport [2,4]. In contrast, glycans present on mature Env after 
biosynthesis are required neither for HIV binding to, nor for 
infection of, CD4+ cells [8-lo] although glycans may help HIV 
to escape host immune response [l 11. The contribution of HIV 
glycans in the stabilization of the mature Env has been sug- 
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gested on several occasions [6,8,9,1 l] but no study has adressed 
this point. Yet, stabilization of gp160 through its glycans is an 
important point inasmuch as removal of gp 160 glycan padding 
may improve its immunogenicity. 
The mature HIV-l glycoproteins, outer membrane gp120 
and transmembrane gp4 1, are proteolytic cleavage products of 
precursor gp160. They are responsible for HIV binding to 
CD4+ cells and fusion of virus and cell membranes, respectively 
[12]. gp160 displays a property of the cleaved gp120 subunit, 
i.e. CD4 binding [12]. It is highly glycosylated: glycans are 
conserved between isolates, equally distributed on Env and 
responsible for 50% of its MW [13]. Recombinant and viral 
gp160 exhibit a similar pattern of large high mannose and 
complex type glycans [8,9,13]. Possibly, this mass of glycans is 
a selective advantage for HIV by protecting mature Env against 
degradations. 
gp160 has an elaborate organisation with variable and con- 
served loops bridged by 10 disulfide bonds [ 121. These loops 
interact each other to form the conformation that binds CD4 
[ 121. Using CD4 binding ability to study Env conformation, we 
investigated the role of glycans in the protection of gp160 
against degradations induced by various treatments. 
2. Materials and methods 
2.1. Reagents 
Mouse monoclonal (m) antibody (Ab)41a9 (a gift from F. Traincard, 
Hybridolab, Paris, F) recognizes gp41 amino acids 605-609. Soluble (s) 
gp160 was encoded by a gene where gp120-gp41 cleavage sites and the 
transmembrane domain are missing; it was produced in BHK-21 cells 
via a vaccinia virus vector and purified [14]; sCD4 (a gift from I.M. 
Jones, NERC, Oxford, UK) was obtained in the baculovirus expression 
system. 
2.2. Labeling procedures 
CD4 (5 ,ug in 40 ~1 of PBS NaCl 150 mM pH 7.4 (PBS)) was labeled 
with 150 ,Li of lZ51Na in a 4 nM iodogen-coated tube for 20 min at 
20°C (specific radioactivity: 15 ,&i/pg) [S]; 5 fig of gp160 in 100 ~1 of 
PBS H,O, (l/lo6 final dilution) was labeled with 250 @Zi of “‘INa and 
2.5 pg of lactoperoxidase (specific radioactivity: 25 pCi/pg) [8]. 
2.3. CD4 binding assay 
41a9 mAb (1.5 &lo0 ~1 50 mM bicarbonate buffer pH 9.6) was 
adsorbed onto Maxisorp microtiter plates (Nunc, Roskild, Denmark) 
overnight at 4°C. All subsequent steps were done at 20°C. The wells 
were blocked using 2% non fat dry milk in PBS (PBSM) that was used 
in the following steps. Either a fixed gp160 concentration (for determi- 
nation of denaturing conditions) or increasing concentrations (for ex- 
periments using gp160 treated by N-glycanase (CHO-) as in [8,9,15]) 
were added. In competitive experiments, 100 ng of gp160 were incu- 
bated for 2 h in mAb-coated wells. After a wash, CD4 (2-200 nM) and 
[‘*51]CD4 (2’ IO“ cpm/well) were coincubated for 2 h. After 3 washes, 
radioactivity was counted. Background was measured by incubating 
[‘?]CD4 directly with the mAb. To ascertain that neither physical 
(temperature of freeze/thaw cycles) nor chemical (guanidine-HCL SDS, 
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/?-mercaptoethanol (MSH)) treatments modified gp160 binding to 4la9 
mAb, glycosylated (CHO+) and CHO- [‘2sI]gp160 (2.10’ cpm/assay) 
were similarly treated. Samples were incubated in mAb-coated wells for 
2 h. After 3 washes, radioactivity was counted. Background was deter- 
mined using wells with no mAb but incubated with [‘251]gp160. When 
serum or cell lysate were used, gp160 bound to wells was determined 
by ELISA using human anti-HIV-l sera (I : 100) [9]. 
100 
80 
2.4. gpl60 treatments 
In each experiment described below, the effect of the pretreatment 
on gpl60-mAb binding and CD4 binding was checked as described 
above. (i) SDS treatment: gp160 (100 ng/lOpl PBS) was incubated with 
SDS (0 to 3%) for 10 min at 20°C and then diluted in 100~1 PBSM prior 
the assay. Similarly, CHO+ gp160 and CHO- gp160 (750 ng) were 
treated in 17 ,uI PBS and diluted IO-fold prior the assay. (ii) MSH 
treatment: gp160 (100 ng/lOpl PBS) was treated with MSH (0 to 0.3%) 
for 10 min at 20°C and then with iodoacetamide (2.5 : I, iodoacetamidel 
MSH ratio), lyophilized to remove MSH, and diluted in 100 ~1 of 
PBSM, 10% fetal calf serum prior the assay. Similarly, CHO+ gp160 
and CHO- gp 160 (750 ng) were treated in 17 ,uI PBS and diluted IO fold 
prior the assay. (iii) Guanidine-HCI treatment: gp160 (500 ng/5 ,uI) was 
treated with 2 M guanidine-HC1 for 2 h at 20°C and diluted in 500 ,uI 
PBSM prior the assay. Similarly, CHO+ gp160 and CHO- gp160 (2 
pg) were treated in 7~1 ofPBS and then diluted lOO-fold. (iv) Resistance 
to freeze-thaw cycles: gp160 was submitted to up to 15 freeze-thaw 
cycles (one cycle consisted of incubation at -80°C for 5 min in an 
ethanol bath followed by an incubation at +3O”C for 5 min) prior the 
assay. (v) Resistance to temperature: gp160 was heated to definite 
temperatures (20°C to 90°C) for 5 min in a water bath prior the assay. 
(vi) Incubation with serum or cell lysate: serum was obtained from a 
healthy person; cell lysate was obtained by a 3 freeze-thaw cycle treat- 
ment of BHKZI cells (lO’cells/lOO~l). gp160 was treated with 15~1 of 
either serum or cell lysate in PBS (30~1 final volume) overnight at 37°C. 
Samples were diluted at least 5-fold prior the assay. 
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3. Results 
3. I. Evaluation of the CD4 binding assal 
We showed previously [8] that, while CHO+ gpl60 binding 
to CD4 exhibits a K,, 5 of 1.25.10-* M, completely deglycosyl- 
ated gpl60 binds with high affinity cell membrane CD4 
(K,,,5 = 5. lo-’ M) [8,9]. Here, we verified that [?]CD4 binding 
to gp160 adsorbed onto 4la9 mAb-coated wells fullfilled the 
criteria of a specific high affinity interaction. We also verified 
that the assay allowed quantitative measurement of the binding. 
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MAb 41a9 was used because (i) it recognizes with high affin- 
ity (3. IO-“’ M; F. Traincard, personal communication) a region 
that is not involved in CD4 binding and (ii) gpl60 deglycosyla- 
tion does not affect its binding (not shown). Labeled CD4 
migrated as a single sharp band in SDS PAGE (not shown). It 
was bioactive because (i) gp160 binding was inhibited by CD4 
and (ii) the affinity (K,,,, = 7. 10m9 M) was in line with previous 
data [8,9] (Fig. 1A). After N-glycanase treatment, CHO- gpl60 
migrated as a 90 kDa band (not shown). [‘251]CD4 bound 
CHO- gpl60 in a dose dependent manner but its binding was 
3-fold lower than that of CHO+ gpl60 (Fig. IB). 
Fig. 1. Evaluation of the gp160-CD4 binding assay. (A) Affinity of 
native gp160 for [‘251]CD4. After binding onto 41a9 mAb-coated wells, 
gp160 (100 ng) was coincubated with CD4 (2-200 nM) and [?]CD4 
(50 000 cpm)..Bound radioactivity was counted. (B) Effect of the degly- 
cosvlation of ~0160 on CD4 binding. After incubation of either CHO+ 
(@-or CHOr gp160 (0) (5-300 ig) onto 41a9 mAb-coated wells, 
[“‘I]CD4 was added and radioactivity was counted. A representative 
experiment (n = 3) is shown. 
3.2. CD4 binding ability of‘gpl60 submittrd to various 
treatments 
We first determined concentrations of various chemical 
agents that affect protein conformation. CHO+ gpl60 was 
treated with these reagents and its subsequent ability to bind 
CD4 was studied (n = 3) under conditions where these reagents, 
except those bound to treated Env, were no more present in the 
assay as. after mAb binding. wash was done. Concentrations 
above 0.01% of SDS or MSH inhibited CD4 binding while 
binding was abolished with 0.3% and 0.03%, respectively (Fig. 
2A,B). Treatment of gpl60 with 2 M guanidine-HCI did not 
significantly modify CD4 binding while concentrations above 
3 M interfered with mAb binding (not shown). We studied also 
the influence of physical denaturations on gpl60: 2 freeze-thaw 
cycles significantly diminished binding but subsequent cycles 
(up to 15) had little further effect (Fig. 2C and data not shown). 
CD4 binding was modified by preincubation at temperature 
over 50°C and binding was abolished above 80°C (Fig. 2D). 
Incubation with either serum or cell lysate (50%) did not signif- 
icantly alter gpl60-CD4 binding (not shown). 
In each experiment, gpl60-4la9 mAb binding was assessed 
using treated [‘251]gp160. The conditions reported above did not 
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Fig. 2. Effect of physico-chemical treatments of native gp160 on its subsequent ability to bind CD4. gp160 was pretreated with increasing 
concentrations of either SDS (0.003-3%) (A) or MSH (0.003-0.3%) (B), or subjected to freeze-thaw cycles (C) or preincubated at various temperatures 
(30-90°C) (D). CD4 binding was then tested as described in Fig. 1. A representative experiment (n = 3) is shown. 
significantly modify the binding. In addition, [“‘I]CD4 binding 
specificity was assessed in each experiment by incubation with 
an excess of CD4 (not shown). Similar controls were also car- 
ried out in the experiments described below with both CHO+ 
gp160 and CHO- gp160: no significant difference in the mAb 
binding step was noted (not shown). 
3.3. CD4 binding ability of deglycosylated gp160 submitted to 
various treatments 
To study the role of glycans in the protection of gp160 con- 
formation against denaturations, CHO+ and CHO- gp160 
were submitted to the treatments described above. To detect 
with a reliable efficiency any fragilization of CHO- gp160, we 
chose the most severe conditions under which CD4 binding was 
detectable (e.g. 0.01% MSH and SDS, 70°C incubation and 4 
freeze-thaw cycles). Guanidine-HCl (2 M), serum (50%) and 
cell lysate (50%) incubations were performed at the highest 
concentration usable. 
The binding of CHO- gp160 treated with SDS or MSH (Fig. 
3A,B) was 4 fold lower than that of CHO+ gp160. This is 
comparable with results obtained in Fig. 1B: thus, glycan re- 
moval did not alter gp160 resistance to SDS and MSH treat- 
ments. In contrast, 2 M guanidine-HCl treatment which had no 
effect on CHO+ gp160-CD4 binding, strongly impaired CHO- 
gpl60CD4 binding (Fig. 3C). Similarly, incubation at 70°C 
which only slightly affected CHO+ gp160-CD4 binding, im- 
paired CHO- gpl60-CD4 binding (Fig. 4A). CHO+ gp 160 and 
CHO- gp160 were similarly resistant to freeze-thaw cycles (Fig. 
4B). Incubation in serum or cell lysate for 24 h at 37°C altered 
CD4 binding of the sole CHO- gp160 (Fig. 5A,B). 
4. Discussion 
Glycans are neccesary for HIV Env folding [3,6] while they 
appear dispensable after biosynthesis to maintain its functional 
conformation [3,6,8,10]: completely [8] deglycosylated gp120 
binds with high affinity CD4 (K,,, = 5. lo-’ M for CHO- gp120 
and 1.25.10-* M for native gp120) [8810]. However, the pres- 
ence of 0.025% SDS during the deglycosylation procedure al- 
ters subsequent CD4 interaction [16]. Thus, a low SDS concen- 
tration, which does not affect native gp120 conformation, has 
a large effect on the conformation of its deglycosylated counter- 
part. This suggests that glycan removal alters gp160 stability. 
To verify this point, we studied the role of the glycans of 
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Fig. 3. CD4 binding ability of deglycosylated gp160 submitted to chem- 
ical treatments. CHO+ (m) and CHO- (II) gp160 were treated with 
0.01% SDS (A), 0.01% MSH (B), 2 M guanidine-HCl (C). CD4 binding 
was then tested as described in Fig. 1. A representative experiment 
(n = 3) is shown. 
recombinant gp160 in its protection against various physico- 
chemical denaturation agents and in its stability in serum or cell 
lysate, through its subsequent CD4 binding ability. This ap- 
proach to detect conformation changes was prefered to assays 
based on antibodies the reactivity of which can be altered by 
the removal of glycans in the absence of protein conformation 
changes. 
First, we designed an assay in which [?]CD4 binds gpl60 
adsorbed onto anti-gp160 mAb coated wells: the affinity was 
7.1 Om9 M and deglycosylated gpl60 bound CD4 with an ability 
reduced by only 3-fold, consistent with previous results [8,12]. 
Treatment of gpl60 with 0.01% SDS was followed by a 
substantial decrease in subsequent CD4 binding and binding 
was abolished at 0.3%. This is in line with denaturation by 0.2% 
SDS of P-lactoperoxidase and ribonuclease [ 171. However, 
many proteins, such as glucose oxidase or papain, remain active 
in the presence of 1% SDS [18]. Thus, gp160 appears to be 
rather sensitive to SDS denaturation. 
gpl60 bound CD4 following treatment with up to 0.01% 
MSH but activity was abolished at 0.03% MSH (gpl60/MSH 
molar ratio, 1:60,000). The disulfide bond/MSH molar ratio 
usually used to reduce denatured protein is about l/l00 [19] but 
reduction of disulfide bonds of native molecules depends on 
their accessibility: an IgG/MSH molar ratio of 1: 1,000 only 
reduces the disulfide bond between heavy and light chains of 
native 1gG but all intra- and inter-disulfide bonds of denatured 
IgG [20,21]. Thus, disulfide bonds appear poorly sensitive to 
MSH on native gpl60. Of note, treatment with 0.01% MSH or 
SDS increased subsequent gpl60-CD4 binding, possibly 
through conformation changes which may promote gpl60- 
CD4 interaction. 
Guanidine-HCl(2 M) treatment had no significant effect on 
CD4 binding but this condition is sufficient to alter many pro- 
teins [22], e.g. ribonuclease [23], erythropoetin [24], galactose 
oxydase [25] and yeast invertase [26]. The inactivation of the 
latter enzymes is reversed by dilution of the sample: thus, 2 M 
guanidine-HCl may alter gp160 conformation in a reversible 
way that can be achieved by dilution during the assay. 
Temperatures below 50°C did not alter CD4 binding but 
binding was abolished above 80°C. Resistance of proteins to 
heat denaturation varies: galactose oxidase activity decreases 
after 30 min at 60°C [2.5] while erythropoietin remains active 
after 30 min at 70°C [27]. However, erythropoietin is denatured 
at around 55°C as assessed by circular dichroism analysis [24] 
and the activity of the heat-treated molecule is due to renatura- 
tion. Thus, Env structure may be reversibly altered by temper- 
atures below 70°C and may progressively lose its ability to 
refold at higher temperatures. 
CD4 binding decreased by 50% following 2 freeze-thaw 
cycles and subsequent cycles had little effect. Freeze-thaw cy- 
cles denature many proteins [28] but it is not a general phenom- 
enon: invertase activity resists to 40 freeze-thaw cycles [26] and 
glucose oxidase to 100 cycles [25]. The mechanism of freeze- 
thaw denaturation is imputed to the formation of ice within the 
molecule. This induces an increase in the concentration of sub- 
stances originally in solution in the environment of the mole- 
cule. Freezing injury can thus be compared with osmotic salt 
injury [29]. 
We examined whether glycans stabilize gp160 conformation. 
We treated CHO+ and CHO- gp160 with the conditions deter- 
mined above. Only guanidine-HCl and heating affected differ- 
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Fig. 4. CD4 binding ability of deglycosylated gp160 submitted to phys- 
ical treatments. CHO+ (m) and CHO- (CI) gp160 were submitted to 
heating at 70°C (A) or to 4 freeze-thaw cycles (B). CD4 binding was 
then tested as described in Fig. 1. A representative experiment (n = 3) 
is shown. 
entially CD4 binding ofCHO+ gp160 and CHO- gp160. Thus, 
gp160 glycans have a protective role against some denaturing 
agents. The stabilizing role of glycans depends on the glycopro- 
tein [5,30]: both glycosylated and non glycosylated ribonu- 
cleases are equally sensitive to guanidine-HCl and refold 
equally well [23] while CHO- yeast invertase progressively 
looses its activity following freeze-thaw cycles whereas its 
CHO+ counterpart does not. The activity of its two forms is 
similarly affected by guanidine-HCl but its removal allows re- 
covery of the activity of CHO+ but not of CHO- invertase [26], 
suggesting that glycans influence refolding. Similarly, native 
erythropoietin unfolds at 70°C [24] but its activity is restored 
once the temperature decreases, while its CHO- counterpart 
is irreversibly affected [27]. Thus, glycans of HIV Env may 
either stabilize its structure or be involved in refolding after 
denaturation. The latter is more likely as CHO- gp160 activity 
was affected by treatments which may be reversed here. 
Finally, glycans play a role in the stabilization of gp160 in 
media that may contain proteases, e.g. serum or cell lysate, 
inasmuch as they only alter CD4 binding by CHO- gp160. 
Similar protection is described for many glycoproteins [5,30- 
32] and may be due to removal of bulky glycans exposing 
proteolytic sites either by inducing conformation changes of the 
tertiary structure or by unmasking cleavage sites. 
In conclusion, CHO- gp160 appears to be rather resistant 
to many denaturing agents. The use of abnormally glycosylated 
gp160 as immunogen was considered as a means to improve the 
anti-HIV immune response as glycosylation may mask neutral- 
izing epitopes. Because deglycosylation decreases gp160 stabil- 
ity, especially in serum, the characterization of abnormally gly- 
cosylated forms with higher stability, and thus with improved 
plasma half-life, should be investigated to help vaccine design. 
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